Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes.

Abstract

OBJECTIVE:

To compare the short-term effects of rosuvastatin and simvastatin on insulin-resistance and endothelial dysfunction in middle-aged patients with type 2 diabetes and mild untreated dyslipidemia.

METHODS AND DESIGN:

29 Subjects randomly assigned to rosuvastatin 20mg/daily or simvastatin 20mg/daily for 4 weeks. Following data collected both pre- and post-treatment: fasting glucose, lipids, hs CRP, TNF-alpha, insulin sensitivity measured with euglycemic-hyperinsulinemic clamp and flow-mediated dilation with brachial artery reactivity technique.

RESULTS:

Both treatments markedly reduced LDL cholesterol (p<0.001 for both). Insulin sensitivity did not change from relative baseline values in both groups, as well as fasting glucose and adiponectin. Simvastatin significantly improved flow-mediated dilation (p<0.01), to a greater extent than in patients taking rosuvastatin (p=0.09). We found no association between flow-mediated dilation improvement, LDL reduction and changes in hs CRP levels.

CONCLUSION:

In type 2 diabetic individuals rosuvastatin was less effective than simvastatin at improving endothelium-dependent vasodilation within one month, without affecting insulin-resistance, adiponectin levels and inflammation.

• Authors: Alfonso Bellia, Stefano Rizza, Angelica Galli, Rossella Fabiano, Giulia Donadel, Marco Felice Lombardo, Carmine Cardillo, Paolo Sbraccia, Manfredi Tesauro, Davide Lauro
• Journal: Atherosclerosis (Atherosclerosis) Vol. 210 Issue 1 Pg. 199-201 (May 2010) ISSN: 1879-1484 [Electronic] Ireland
• PMID: 20018286 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright 2009 Elsevier Ireland Ltd. All rights reserved.

Chemical References

• Adiponectin
• Blood Glucose
• Cholesterol, LDL
• Fluorobenzenes
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Lipids
• Pyrimidines
• Sulfonamides
• Tumor Necrosis Factor-alpha
• Rosuvastatin Calcium
• C-Reactive Protein
• Simvastatin

Topics

• Adiponectin (blood)
• Adult
• Blood Glucose (analysis)
• C-Reactive Protein (analysis)
• Cholesterol, LDL (blood)
• Diabetes Mellitus, Type 2 (drug therapy)
• Endothelium, Vascular (drug effects)
• Female
• Fluorobenzenes (administration & dosage, pharmacology, therapeutic use)
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (administration & dosage, therapeutic use)
• Insulin Resistance (physiology)
• Lipids (blood)
• Male
• Middle Aged
• Pyrimidines (administration & dosage, pharmacology, therapeutic use)
• Rosuvastatin Calcium
• Simvastatin (administration & dosage, pharmacology, therapeutic use)
• Sulfonamides (administration & dosage, pharmacology, therapeutic use)
• Tumor Necrosis Factor-alpha (blood)
• Vasodilation (drug effects)